Table 3

Multivariable analysis of CDAI over time

Coeff95% CIP values
Treatment at baseline
 TCZ-SC−0.76−1.70 to 0.190.12
Time, years−8.19−8.87 to −7.51<0.001
Time-squared2.292.05 to 2.54<0.001
Time-cubed−0.18−0.21 to −0.16<0.001
Age, years−0.02−0.06 to 0.010.22
Female gender−0.54−1.66 to 0.580.34
Disease duration, years−0.01−0.07 to 0.050.72
Seropositivity−1.85−3.01 to −0.700.002
BMI0.03−0.05 to 0.120.45
Smoking−0.32−1.20 to 0.550.47
Glucocorticoids1.681.01 to 2.34<0.001
Concomitant csDMARD (base=none)1.040.41 to 1.680.001
 Any csDMARD MTX1.510.81 to 2.21<0.001
 MTX+other csDMARDs0.70−0.60 to 2.000.29
 Other than MTX−0.07−1.04 to 0.900.88
Previous bDMARDs (base=none)
 10.42−0.63 to 1.480.43
 20.80−0.36 to 1.960.18
 ≥30.06−1.63 to 1.740.95
HAQ at baseline3.873.25 to 4.50<0.001
ESR0.250.24 to 0.27<0.001
Comorbidity0.17−0.80 to 1.140.73
  • bDMARD, biological disease-modifying antirheumatic drug; BMI, Body Mass Index; csDMARD, conventional synthetic disease-modifying antirheumatic drug; CDAI, Clinical Disease Activity Index; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MTX, methotrexate; TCZ-IV, intravenous tocilizumab; TCZ-SC, subcutaneous tocilizumab.